The Efficiency of Convalescent Plasma in COVID-19 Patients: A Systematic Review and Meta-analysis of Randomized Controlled Clinical Trials

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2022 Aug 15

PMID 35967398

Authors

Zhenbei Qian

Zhijin Zhang

Haomiao Ma

Shuai Shao

Hanyujie Kang

Zhaohui Tong

Affiliations

Soon will be listed here.

Abstract

Trial Registration Number: CRD42021273608. Registration on February 28, 2022.

Systematic Review Registration: https://www.crd.york.ac.uk/prospero/, Identifier CRD42022313265.

Citing Articles

Combating Emerging Respiratory Viruses: Lessons and Future Antiviral Strategies.

Muthukutty P, MacDonald J, Yoo S Vaccines (Basel). 2024; 12(11).

PMID: 39591123 PMC: 11598775. DOI: 10.3390/vaccines12111220.

Combination of spironolactone and DPP-4 inhibitors for treatment of SARS-CoV-2 infection: a literature review.

Asadipooya K, Asadipooya A, Adatorwovor R Arch Virol. 2024; 169(6):122.

PMID: 38753071 DOI: 10.1007/s00705-024-06043-1.

Facing the Challenges in the COVID-19 Pandemic Era: From Standard Treatments to the Umbilical Cord-Derived Mesenchymal Stromal Cells as a New Therapeutic Strategy.

Russo E, Corrao S, Di Gaudio F, Alberti G, Caprnda M, Kubatka P Cells. 2023; 12(12).

PMID: 37371134 PMC: 10297457. DOI: 10.3390/cells12121664.

Coronavirus Disease-2019 in Pregnancy.

Rojas-Suarez J, Miranda J Clin Chest Med. 2023; 44(2):373-384.

PMID: 37085226 PMC: 9682053. DOI: 10.1016/j.ccm.2022.11.015.

References

Gordon A, Mouncey P, Al-Beidh F, Rowan K, Nichol A, Arabi Y . Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. N Engl J Med. 2021; 384(16):1491-1502. PMC: 7953461. DOI: 10.1056/NEJMoa2100433. View

Korley F, Durkalski-Mauldin V, Yeatts S, Schulman K, Davenport R, Dumont L . Early Convalescent Plasma for High-Risk Outpatients with Covid-19. N Engl J Med. 2021; 385(21):1951-1960. PMC: 8385553. DOI: 10.1056/NEJMoa2103784. View

Chauhan L, Pattee J, Ford J, Thomas C, Lesteberg K, Richards E . A Multicenter, Prospective, Observational, Cohort-Controlled Study of Clinical Outcomes Following Coronavirus Disease 2019 (COVID-19) Convalescent Plasma Therapy in Hospitalized Patients With COVID-19. Clin Infect Dis. 2021; 75(1):e466-e472. PMC: 9612788. DOI: 10.1093/cid/ciab834. View

. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. Lancet. 2021; 397(10289):2049-2059. PMC: 8121538. DOI: 10.1016/S0140-6736(21)00897-7. View

Bar K, Shaw P, Choi G, Aqui N, Fesnak A, Yang J . A randomized controlled study of convalescent plasma for individuals hospitalized with COVID-19 pneumonia. J Clin Invest. 2021; 131(24). PMC: 8670841. DOI: 10.1172/JCI155114. View

Sterne J, Murthy S, Diaz J, Slutsky A, Villar J, Angus D . Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis. JAMA. 2020; 324(13):1330-1341. PMC: 7489434. DOI: 10.1001/jama.2020.17023. View

Cho K, Keithly S, Kurgansky K, Madenci A, Gerlovin H, Marucci-Wellman H . Early Convalescent Plasma Therapy and Mortality Among US Veterans Hospitalized With Nonsevere COVID-19: An Observational Analysis Emulating a Target Trial. J Infect Dis. 2021; 224(6):967-975. PMC: 8411382. DOI: 10.1093/infdis/jiab330. View

Balcells M, Rojas L, Le Corre N, Martinez-Valdebenito C, Ceballos M, Ferres M . Early versus deferred anti-SARS-CoV-2 convalescent plasma in patients admitted for COVID-19: A randomized phase II clinical trial. PLoS Med. 2021; 18(3):e1003415. PMC: 7929568. DOI: 10.1371/journal.pmed.1003415. View

Ali S, Uddin S, Shalim E, Sayeed M, Anjum F, Saleem F . Hyperimmune anti-COVID-19 IVIG (C-IVIG) treatment in severe and critical COVID-19 patients: A phase I/II randomized control trial. EClinicalMedicine. 2021; 36:100926. PMC: 8177439. DOI: 10.1016/j.eclinm.2021.100926. View

10.

. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2022; 399(10325):665-676. PMC: 8830904. DOI: 10.1016/S0140-6736(22)00163-5. View

11.

Liu S, Lin H, Baine I, Wajnberg A, Gumprecht J, Rahman F . Convalescent plasma treatment of severe COVID-19: a propensity score-matched control study. Nat Med. 2020; 26(11):1708-1713. DOI: 10.1038/s41591-020-1088-9. View

12.

Hassanipour S, Arab-Zozani M, Amani B, Heidarzad F, Fathalipour M, Martinez-de-Hoyo R . The efficacy and safety of Favipiravir in treatment of COVID-19: a systematic review and meta-analysis of clinical trials. Sci Rep. 2021; 11(1):11022. PMC: 8155021. DOI: 10.1038/s41598-021-90551-6. View

13.

Rasheed A, Fatak D, Hashim H, Maulood M, Kabah K, Almusawi Y . The therapeutic potential of convalescent plasma therapy on treating critically-ill COVID-19 patients residing in respiratory care units in hospitals in Baghdad, Iraq. Infez Med. 2020; 28(3):357-366. View

14.

Estcourt L, Turgeon A, McQuilten Z, McVerry B, Al-Beidh F, Annane D . Effect of Convalescent Plasma on Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial. JAMA. 2021; 326(17):1690-1702. PMC: 8491132. DOI: 10.1001/jama.2021.18178. View

15.

Focosi D, Franchini M, Pirofski L, Burnouf T, Paneth N, Joyner M . COVID-19 Convalescent Plasma and Clinical Trials: Understanding Conflicting Outcomes. Clin Microbiol Rev. 2022; 35(3):e0020021. PMC: 9491201. DOI: 10.1128/cmr.00200-21. View

16.

Moher D, Liberati A, Tetzlaff J, Altman D . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009; 6(7):e1000097. PMC: 2707599. DOI: 10.1371/journal.pmed.1000097. View

17.

Tang J, Grubbs G, Lee Y, Golding H, Khurana S . Impact of Convalescent Plasma Therapy on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibody Profile in Coronavirus Disease 2019 (COVID-19) Patients. Clin Infect Dis. 2021; 74(2):327-334. PMC: 8083369. DOI: 10.1093/cid/ciab317. View

18.

Yang P, Wang J, Zheng R, Tan R, Li X, Liu X . Convalescent plasma may not be an effective treatment for severe and critically ill covid-19 patients: A Systematic Review & Meta-Analysis of Randomized Controlled Trials. Heart Lung. 2022; 53:51-60. PMC: 8806131. DOI: 10.1016/j.hrtlng.2022.01.019. View

19.

Axfors C, Janiaud P, Schmitt A, Vant Hooft J, Smith E, Haber N . Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials. BMC Infect Dis. 2021; 21(1):1170. PMC: 8605464. DOI: 10.1186/s12879-021-06829-7. View

20.

Egloff S, Junglen A, Restivo J, Wongskhaluang M, Martin C, Doshi P . Convalescent plasma associates with reduced mortality and improved clinical trajectory in patients hospitalized with COVID-19. J Clin Invest. 2021; 131(20). PMC: 8516450. DOI: 10.1172/JCI151788. View